@ascletisp
ID: 1589465332758052864
calendar_today07-11-2022 03:51:52
124 Tweet
14 Followers
0 Following
4 months ago
Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA ascletis.com/news_detail/19…